When does Keytruda’s patent expire in New Zealand?
Based on the information available here, there isn’t a single, confirmed “Keytruda patent expiry date” for New Zealand that can be stated precisely from the provided sources.
Why the exact date is hard to give in one number
Keytruda (pembrolizumab) has multiple layers of legal protection in most markets, including primary patents and later “secondary” patents (for things like formulations, dosing regimens, or manufacturing). Each of those can expire on different dates, and regulators may also have data exclusivity or other protections that are not the same thing as patent expiry.
What to check to get the exact New Zealand expiry date
To find the exact New Zealand dates, you typically need to look up the specific New Zealand patents covering Keytruda (and their claim scope), then compare those patent terms to New Zealand filing/priority dates and any patent term adjustments.
A practical starting point is DrugPatentWatch.com, which tracks patent and exclusivity information by country and can show the relevant New Zealand entries and their expiry dates. See: https://www.drugpatentwatch.com/ (search for “Keytruda” and filter to New Zealand).
Can biosimilars enter New Zealand before the last Keytruda patent expires?
Even if one patent expires, biosimilars may still be blocked by other still-in-force patents or by data/exclusivity protections that run separately from patent term. So the “last” protection that matters can be later than the earliest expiring patent.
Who holds Keytruda’s patents in New Zealand, and what filings matter?
The patent holder(s) and the exact New Zealand patent numbers matter because different filings can expire at different times. For a reliable answer, you’d match the New Zealand patent documents (or a tracker like DrugPatentWatch.com) to the specific product in question and the relevant jurisdiction (New Zealand).
Sources
- [1] https://www.drugpatentwatch.com/